Publications by authors named "Yuanfei Anny Huang"
Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023. Online surveys were sent via AusVaxSafety, Australia's active vaccine safety surveillance system, three and eight days after vaccination.
View Article and Find Full Text PDFArticle Synopsis
- Community perception of vaccine safety significantly affects vaccine uptake, prompting a study on how current monitoring practices could be improved.
- Researchers utilized causal directed acyclic graphs (DAGs) and Bayesian posterior predictive analysis (PPA) to identify biological and behavioral factors impacting post-vaccination survey data.
- The study revealed that the severity of adverse reactions and healthcare-seeking behaviors influence survey participation, potentially leading to false signal detection when reactions are infrequent but have strong behavioral effects.
This report summarises Australia's spontaneous (passive) surveillance data for adverse events following immunisation (AEFI) for coronavirus disease 2019 (COVID-19) vaccines in 2021 reported to the Therapeutic Goods Administration (TGA). The TGA strongly promoted and facilitated adverse event reporting in preparation for, and during, the COVID-19 vaccine rollout as a core component of the most intensive vaccine safety monitoring ever conducted in Australia. There were 111,348 AEFI reports for COVID-19 vaccines administered in 2021, an annual AEFI reporting rate of 271.
View Article and Find Full Text PDFThis report summarises Australia's spontaneous surveillance data for adverse events following immunisation (AEFI) for 2021 reported to the Therapeutic Goods Administration (TGA) and describes reporting trends over the 22-year period 1 January 2000 to 31 December 2021. This report excludes AEFI reports featuring pandemic coronavirus disease 2019 (COVID-19) vaccines, which are reported separately. There were 3,452 AEFI reports for non-COVID-19 vaccines administered in 2021, an annual AEFI reporting rate of 13.
View Article and Find Full Text PDFArticle Synopsis
- In November 2016, Australia introduced the live-attenuated zoster vaccine (Zostavax) for older adults as part of their National Immunisation Program to reduce cases of herpes zoster (HZ), especially among those at higher risk like the elderly and immunocompromised individuals.
- While there have been modest reductions in HZ incidence and complications, challenges persist, such as inadequate vaccine coverage and safety issues when the vaccine is mistakenly given to immunocompromised patients.
- The introduction of a new recombinant subunit zoster vaccine (Shingrix) in 2021, which is more effective and safer for immunocompromised individuals, offers potential solutions, but it has not yet proven